ABBV-951 is designed to provide 24-hour continuous subcutaneous delivery of the combination carbidopa/levodopa medication, the company said.
The FDA submission is based on results from a phase 3 clinical trial in which ABBV-951 showed "statistically significant improvement" in controlling involuntary movements in advanced Parkinson's disease patients compared with oral immediate-release carbidopa/levodopa, AbbVie said.
The company will continue to seek regulatory submissions for ABBV-951 across international markets this year, it said.
Price: 152.96, Change: +1.24, Percent Change: +0.82